Patent details

Basic Information

Publication number:

93001

Type:

SPC

SPC Type:

Medical

Basic Patent Number:

EP101852770

Legal Status:

Active

Application number:

93001

First applicant's nationality:

Procedural language:

French

Marketing Authorization

Marketing Authorization Number:

EU/1/14/937 - Gazyvaro-Obinutuzumab

Marketing Authorization Type:

Marketing Authorization Date:

24/07/2014

Marketing Authorization Status:

Accepted

Marketing Authorization Country:

Dates

Filing date:

14/03/2016

First Marketing Authorization date:

24/07/2014

Grant date:

17/05/2016

Activation date:

05/11/2024

Publication date:

17/05/2016

Lapsed date:

Expiration date:

Renunciation date:

Revocation date:

Annulment date:

Basic SPC Expiration:

24/07/2029

SPC Extension Expiration:

24/07/2029

Rejection date:

Withdrawal date:

Owner

From:

14/03/2016

 

 

Name:

Roche Glycart AG

Address:

Wagistrasse 18, 8952 Schlieren-Zuerich, Switzerland (CH)

Agent

Name:

OFFICE FREYLINGER S.A.

From:

14/03/2016

Address:

Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)

To:

Inventor

1

Name:

Umana Pablo

Address:

Switzerland (CH)

2

Name:

Brünker Peter

Address:

Switzerland (CH)

3

Name:

Püntener Ursula

Address:

United Kingdom (GB)

4

Name:

Suter Tobias

Address:

Switzerland (CH)

5

Name:

Ferrara Koller Claudia

Address:

Switzerland (CH)

6

Name:

Mössner Ekkehard

Address:

Switzerland (CH)

Publication

Bulletin

Bulletin Heading:

SPC3

Bulletin edition number:

2025/04

Publication date:

04/03/2025

Description:

Section E : Supplementary Protection certificates entered into force – IA publication

Annual Fees

Annual Fee Due Date:

30/11/2026

Annual Fee Number:

23

Annual Fee Amount:

430 Euro

Expected Payer:

Last Annual Fee Payment Date:

23/07/2025

Last Annual Fee Paid Number:

22

Last Annual Fee Paid Amount:

420 Euro

Payer:

ANAQUA SERVICES (ANC. SGA2)

Filing date	Document type	Number of pages